BioCorRx (BICX) Accumulated Expenses (2013 - 2026)

BioCorRx has disclosed Accumulated Expenses across 10 years of filings, most recently posting $351492.0 for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $351492.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $351492.0 (changed N/A YoY), and the FY2025 annual result was $359378.0, changed N/A from the prior year.
• Accumulated Expenses came in at $351492.0 for Q1 2026 at BioCorRx, down from $359378.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $359378.0 in Q4 2025 to a low of $1292.0 in Q1 2022.
• The 3-year median for Accumulated Expenses is $147871.0 (2025), against an average of $172337.0.
• Peak annual rise in Accumulated Expenses reached 452.51% in 2022, while the deepest fall reached 452.51% in 2022.
• BioCorRx's Accumulated Expenses stood at $1652.0 in 2022, then surged by 21654.12% to $359378.0 in 2025, then fell by 2.19% to $351492.0 in 2026.
• The last three Accumulated Expenses figures came in at $351492.0 (Q1 2026), $359378.0 (Q4 2025), and $147871.0 (Q2 2025), per Business Quant data.